Skip to main content
. Author manuscript; available in PMC: 2020 Aug 31.
Published in final edited form as: Invest New Drugs. 2016 Jul 21;34(6):733–739. doi: 10.1007/s10637-016-0376-1

Table 3:

Treatment Related Toxicities of Cabozantinib and Gemcitabine (n=11 evaluable patients).

Adverse Event Grade 1 (n) Grade 2 (n) Grade 3 (n) Grade 4 (n)
Hematologic
 Anemia 5 3 - -
 Neutropenia 1 1 5 -
 Thrombocytopenia 2 2 2 -
Non-Hematologic
  Fatigue 5 1 - -
  Flu-like symptoms - - 1 -
  Diarrhea 2 1 - -
  Nausea 6 - - -
  Mucositis 1 - - -
  AST/ALT Elevations 2 3 5 -
  Hypertension - 3 1 -
  Proteinuria - 1 - -
  Alopecia 2 - - -
  Myalgia 1 1 - -

Grading of severity of adverse events based on NCI CTCAE v4.0.